First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.

Autor: Lee SM; Department of Oncology, University College London Hospitals NHS Foundation Trust, CRUK Lung Cancer Centre of Excellence and UCL Cancer Institute, London, UK. Electronic address: sm.lee@nhs.net., Schulz C; Bereich Pneumologie Klinik und Poliklinik für Innere Medizin II, University Hospital Regensburg, Regensburg, Germany., Prabhash K; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India., Kowalski D; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Szczesna A; Department of Lung Diseases, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock, Poland., Han B; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China., Rittmeyer A; Department of Thoracic Oncology, LKI Lungenfachklinik Immenhausen, Immenhausen, Germany., Talbot T; Department of Oncology, Royal Cornwall Hospitals NHS Trust, Truro, UK., Vicente D; Medical Oncology Department, Hospital Universitario Virgen Macarena, Seville, Spain., Califano R; Department of Medical Oncology, The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, UK., Cortinovis D; Department of Medical Oncology, AAST H S Gerardo Monza, Monza, Italy., Le AT; Cho Ray Cancer Centre, Cho Ray Hospital, Ho Chi Minh City, Viet Nam., Huang D; Department of Thoracic Oncology, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Liu G; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Cappuzzo F; Department of Oncology, National Cancer Institute IRCCS Regina Elena, Rome, Italy., Reyes Contreras J; Oncologico Potosino, San Luis Potosí, Mexico., Reck M; Department of Thoracic Oncology, Lungen Clinic Grosshansdorf, Airway Research Centre North, German Centre for Lung Research, Grosshansdorf, Germany., Palmero R; Department of Medical Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain., Mak MP; Department of Medical Oncology, Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil., Hu Y; F Hoffmann-La Roche, Basel, Switzerland., Morris S; F Hoffmann-La Roche, Basel, Switzerland., Höglander E; F Hoffmann-La Roche, Basel, Switzerland., Connors M; Genentech, San Francisco, CA, USA., Biggane AM; F Hoffmann-La Roche, Basel, Switzerland; Pfizer, Kent, UK., Vollan HK; F Hoffmann-La Roche, Basel, Switzerland., Peters S; Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.

Publikováno v: Lancet (London, England) [Lancet] 2023 Aug 05; Vol. 402 (10400), pp. 451-463. Date of Electronic Publication: 2023 Jul 06.

Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer.

Autor: Ardizzoni A; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy andrea.ardizzoni@aosp.bo.it., Azevedo S; Oncology Service, Unidade de Pesquisa Clinica, Hospital de Clínicas de Porto Alegre, Bologna, Italy., Rubio-Viqueira B; Department of Medical Oncology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain., Rodriguez-Abreu D; Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain., Alatorre-Alexander J; Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, Mexico., Smit HJM; Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands., Yu J; Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China., Syrigos K; 3rd Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Höglander E; F Hoffmann-La Roche Ltd, Basel, Switzerland., Kaul M; Genentech Inc, South San Francisco, California, USA., Tolson J; F Hoffmann-La Roche Ltd, Basel, Switzerland., Hu Y; F Hoffmann-La Roche Ltd, Basel, Switzerland., Vollan HK; F Hoffmann-La Roche Ltd, Basel, Switzerland., Newsom-Davis T; Department of Oncology, Chelsea and Westminster Hospital, London, UK.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Nov; Vol. 10 (11).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?

Autor: Bronte, Giuseppe^1,2 (AUTHOR), Cosi, Donato Michele³ (AUTHOR), Magri, Chiara³ (AUTHOR), Frassoldati, Antonio³ (AUTHOR), Crinò, Lucio⁴ (AUTHOR), Calabrò, Luana^3,5 (AUTHOR) luana.calabro@unife.it

Publikováno v: International Journal of Molecular Sciences. Aug2023, Vol. 24 Issue 16, p12622. 20p.